<DOC>
	<DOCNO>NCT02202226</DOCNO>
	<brief_summary>The purpose study evaluate tolerability safety Lu AF35700 repeat oral dosing patient schizophrenia .</brief_summary>
	<brief_title>Safety Tolerability Study Lu AF35700 After Repeated Dosing Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Men woman 18 60 year ( extremes include ) BMI ≤38 Primary diagnosis schizophrenia accord DSMIVTR™ ( cod 295.10 , 295.20 , 295.30 , 295.90 ) Clinical Global Impression Severity Illness ( CGIS ) score ≤4 ( moderately ill ) screen baseline PANSS total score ≤80 Score ≤4 ( moderate ) follow PANSS item screen safety baseline : P7 ( hostility ) , G8 ( uncooperativeness ) Willing hospitalise 4 5 week Safety Baseline Visit The patient experience acute exacerbation require hospitalization within last 6 month The patient experience acute exacerbation require change antipsychotic medication ( reference drug dose ) within last 4 week The patient diagnosis history substance dependence ( except nicotine ) substance abuse accord DSMIVTR® criterion ≤3 month prior screen The patient smoke &gt; 20 cigarette per day Other protocoldefined inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>